The L. acidophilus, DDS-1® and Bifidobacterium, UABla-12™ probiotic strains have been carefully selected by Chr. Hansen and combining the two strains represents an ideal solution for supporting respiratory health in children.
The results of a scientific study that included 240 healthy children aged from 3 to 12 years old showed a significant decrease in the number of days that children were away from daycare or school, as well as fewer lost workdays for caregivers in the probiotic group compared to placebo. A decrease in the duration and degree of respiratory tract discomfort was also observed in the probiotic group compared to the placebo.4
The L. acidophilus, DDS-1® and Bifidobacterium, UABla-12™ strain combination can be produced in multiple dosage forms appropriate for children, such as sachets, chewable tablets, blends and other powder solutions. The combination is available in various flavors and can be customized to your specific needs.
1 Lenoir-Wijnkoop et al. PLoS One, 2015; 10(4):e0122765.
2 Zoorob et al. Am Fam Physician. 2012 Nov 1;86(9):817-822.
3 Lu et al. Child Care Health Dev 2004; 30: 361–8 |
4 Gerasimov SV, Ivantsiv VA, Bobryk LM, et al. Eur J Clin Nutr 2016;70:463-9.
DDS-1® and UABla-12™ are trademarks of Chr. Hansen A/S.